|
|
|
| Clinical study of high-dose Atorvastatin on peripheral blood nuclear factor kappa B in patients with acute coronary syndrome complicated with diabetes mellitus |
| ZENG Hui1 LIU Jun-min1▲ LIN Bo-li2 |
1.Department of Cardiovascular Medicine,Ningdu County People′s Hospital，Ganzhou City,Jiangxi Province,Ningdu 342800,China;
2.Department of Cardiovascular Medicine,Xinfeng County People′s Hospital,Ganzhou City,Jiangxi Province,Xinfeng 341600,China
|
|
|
|
|
Abstract Objective To explore the influence of high-dose Atorvastatin on peripheral blood nuclear factor-kappa B(NF-κB)in patients with acute coronary syndrome(ACS)complicated with diabetes mellitus(DM).Methods From June 2015 to May 2017,100 ACS patients complicated with DM admitted into our hospital were selected and evenly divided into control group (n=50)and experimental group (n=50)in random.Participants in both groups were provided with Atorvastatin for treatment,but with different doses.In the control group,the dose was 10 mg/d,while in the experimental group,the dose was 40 mg/d.The serum biochemical test and the expression and detection of NF-κB were performed before and 4 weeks after the experiment.In addition,the incidence of cardiovascular events was calculated.Results After therapy,the levels of NF-κB,hs-CRP,IL-6,and TNF-α in the two group were all decreased to some extent,and the decrease in the experimental group was more remarkable than that in the control group,which was displayed a statistical inter-group difference(P＜0.05).In the control group,the incidence of cardiovascular events was 20.00%,while 4.00%in the experimental group with a statistical difference(P＜0.05).Conclusion In the treatment of ACS complicated with DM,high-dose Atorvastatin can significantly inhibit NF-κB activity,attenuate inflammation reactions,relieve clinical symptoms,and reduce the incidence of cardiovascular events with an affirmative clinical value.
|
|
|
|
|
|
| [1] |
曹选超，王丽霞，黄改荣，等.普罗布考联合阿托伐他汀对老年急性冠状动脉综合征患者外周血NF-κB表达的影响[J].中华检验医学杂志，2013，36（6）：556-558.
|
| [2] |
李建英.不同剂量阿托伐他汀对老年早期糖尿病肾病患者炎症因子和胰岛素敏感性的影响[J].广西医学，2015，37（1）：37-40.
|
| [3] |
刘新锋，关玲霞，杨昕远.强化阿托伐他汀治疗对ACS合并糖尿病患者炎性因子及血脂的影响[J].中国现代医生，2014，52（28）：32-34.
|
| [4] |
曾洪利，王波，张春玉，等.阿托伐他汀钙对糖尿病大鼠肾脏肿瘤坏死因子α、过氧化物酶体激增剂激活受体γ及核因子κB表达影响的研究[J].中国糖尿病杂志，2013，21（7）：635-637.
|
| [5] |
隋瑜，王春艳，SuiYu，等.阿托伐他汀对急性心肌梗死患者核因子κB65介导炎症反应的作用[J].海军医学杂志，2016，37（1）：40-42.
|
| [6] |
徐先静，黄改荣，段明勤，等.大株红景天注射液联合阿托伐他汀对老年急性冠脉综合征患者的治疗效果[J].郑州大学学报（医学版），2015，50（3）：450-452.
|
| [7] |
毛德军，崔君平，臧运华，等.阿托伐他汀下调肿瘤坏死因子-α诱导的人脐静脉内皮细胞NF-κB的表达[J].细胞与分子免疫学杂志，2013，29（10）：1061-1063.
|
| [8] |
孙元芬，胡小燕，王海滨，等.强化降脂治疗对急性冠脉综合征合并糖尿病老年患者炎症因子和预后的影响[J].中国医刊，2013，48（2）：33-35.
|
| [9] |
刘英，周英，杨海燕，等.不同剂量阿托伐他汀对老年早期糖尿病肾病患者NF-κB、炎性因子及胰岛素抵抗的影响研究[J].海南医学院学报， 2016，22（1）：45-47.
|
| [10] |
张慧敏，刘彦玲，艾辉，等.阿托伐他汀对急性冠脉综合征患者血糖代谢影响的临床研究[J].中国全科医学，2013，16（18）：1623-1625.
|
| [11] |
李建英，郭进，谭文芳，等.老年糖尿病肾病早期患者外周血NF-κB的活化及相关因素的影响[J].广西医学，2012，34（6）：685-688.
|
| [12] |
郭丽婷，高志红，葛焕琦.2型糖尿病患者外周血microRNA-155、细胞核因子-κB和可溶性细胞间黏附分子-1的表达及其与血管并发症的关系研究[J].中国糖尿病杂志，2017，25（3）：213-217.
|
| [13] |
张莹，张浩航，谢毅娟，等.沙格列汀对新诊断2型糖尿病患者血清炎症因子及外周血单个核细胞核因子kB活性的影响[C].中华医学会第十二次全国内分泌学学术会议论文汇编.2013.
|
| [14] |
刘丽军，马燕霞，信栓力，等.阿托伐他汀对急性冠状动脉综合征患者血浆肿瘤坏死因子-α和单核细胞趋化因子-1 水平的影响[J].疑难病杂志，2013，12（2）：129-130.
|
| [15] |
杨明明，程霖，许冰，等.短期胰岛素强化治疗对2型糖尿病患者外周血MCP-1和NF-κB表达的影响[J].海南医学，2017，28（2）：242-245.
|
|
|
|
